Neurogene Announces EMA Grants Orphan Drug Designation for Aspartylglucosaminuria Gene Therapy

Neurogene Inc., a company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announces that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to its adeno-associated virus vector (AAV) with engineered transgene encoding the human AGA gene for patients diagnosed with aspartylglucosaminuria. Aspartylglucosaminuria (AGU) is an inherited rare, progressively debilitating neurodegenerative lysosomal storage disorder. Currently there are no approved treatments to slow or cure AGU in patients living with this disease.

“Due to the lack of approved treatment options and the severity of symptoms, the prognosis and quality of life for patients and families affected by AGU can often be very poor,” said Minna Laine, M.D., Ph.D., Child Neurologist, Helsinki University Hospital, Helsinki, Finland. “The EMA granting Orphan Drug Designation for a potential gene therapy for AGU represents promise while underscoring the urgent, unmet medical need for patients around the world diagnosed with this condition.”

The AGU Orphan Drug Designation represents Neurogene’s third ODD for a rare neurological disease. Earlier this year the U.S. Food and Drug Administration (FDA) granted Neurogene ODD for gene therapies addressing CLN5 and CLN7, two subtypes of Batten disease which are also neurodegenerative and have no available treatment options to slow or halt the disease.

“Gaining this important regulatory milestone designation means we are one step closer to moving the first AGU treatment option into the clinic,” said Rachel McMinn, Ph.D., Neurogene’s Founder and Chief Executive Officer. “Neurogene is collaborating with regulatory authorities, families and patients to make a safe and effective gene therapy for AGU available as quickly as possible.”

About Orphan Drug Designation
EMA orphan designation is designed to encourage the development of new treatments for life-threatening or chronically debilitating conditions that are rare (affecting not more than five in 10,000 people in the European Union). Medicines that meet the EMA’s orphan designation criteria qualify for several incentives, including 10 years of market exclusivity, protocol assistance, and potentially reduced fees for regulatory activities. Applications for orphan designation are examined by the EMA’s Committee for Orphan Medicinal Products (COMP), using the Committee’s network of experts.

To Read the Complete Article at Bussiness Wire, Click Here

Disclaimer: BioPharma Global is not responsible for, and expressly disclaims all liability for, damages of any kind arising out of use, reference to, or reliance on any information contained within the article. Content available through the site may contain links and information to other websites. Links from BioPharma Global to third-party sites do not constitute an endorsement by BioPharma Global of the mentioned parties.

BioPharma Global is a mission-driven corporation, operating like a not-for-profit, dedicated to using our FDA and EMA regulatory expertise and knowledge of various therapeutic areas to help drug developers advance treatments for the disease communities with a high unmet medical need. If you are a drug developer seeking regulatory support for Orphan Drug designation, Fast Track designation, Breakthrough Therapy designation, other FDA/EMA expedited programs, type A, B (pre-IND, EOPs), or C meeting assistance, or IND filings, the BioPharma Global team can help. Contact us today to arrange a 30-minute introductory call.

Stock image by @everythingposs from Depositphotos